Square Pharma - Public Comps and Valuation Multiples

Square Pharma Overview

About Square Pharma

Square Pharmaceuticals PLC is a Bangladesh-based pharmaceutical company engaged in the manufacturing and marketing of generic pharmaceutical products, basic chemical products, animal health products, and crop care products, along with the manufacturing, marketing, and distribution of pharmaceutical products. The company operates in one segment, which is the business of developing, manufacturing, and marketing drugs for health care for all living species. It manufactures drugs such as paracetamol, clotrimazole, antiallergic, nitroglycerin, xylometazoline HCl, erythromycin, and various other drugs, and also provides devices such as AnsuPen and AnsuPen Twist.

Founded

1964

HQ

Employees

15.9K+

Website

squarepharma.com.bd

Sectors

Drug Development & Therapeutics
BioTech

Financials

Last FY Revenue $632M

Last FY EBITDA $233M

EV

$1.0B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Square Pharma Financials

See Square Pharma valuation multiples based on analyst estimates

Square Pharma P&L

In the most recent fiscal year, Square Pharma reported revenue of $632M and EBITDA of $233M.

Square Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Square Pharma valuation multiples based on analyst estimates

	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	XXX	$632M	XXX	XXX	XXX
Gross Profit	XXX	$303M	XXX	XXX	XXX
Gross Margin	XXX	48%	XXX	XXX	XXX
EBITDA	XXX	$233M	XXX	XXX	XXX
EBITDA Margin	XXX	37%	XXX	XXX	XXX
EBIT	XXX	$161M	XXX	XXX	XXX
EBIT Margin	XXX	25%	XXX	XXX	XXX
Net Profit	XXX	$199M	XXX	XXX	XXX
Net Margin	XXX	31%	XXX	XXX	XXX
Net Debt	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Square Pharma including revenue, profitability, and margin analysis across different time periods. In the most recent fiscal year, Square Pharma achieved $632M in revenue and $233M in EBITDA.
Financial Metric	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	Analyst estimates available to subscribers	$632M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	Analyst estimates available to subscribers	$303M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	Analyst estimates available to subscribers	47.9% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	Analyst estimates available to subscribers	$233M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	Analyst estimates available to subscribers	36.8% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	Analyst estimates available to subscribers	$161M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	Analyst estimates available to subscribers	25.4% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	Analyst estimates available to subscribers	$199M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	Analyst estimates available to subscribers	31.4% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Square Pharma

This financial data table provides comprehensive performance metrics for Square Pharma, a company based in Bangladesh. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Fiscal Year Performance

In the most recent fiscal year, Square Pharma reported $632M in total revenue.
Fiscal year EBITDA was $233M.
The company maintained a gross profit margin of 47.9% in the most recent fiscal year.
EBITDA margin for the fiscal year was 36.8%.
Net profit margin reached 31.4% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Square Pharma. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Square Pharma Stock Performance

Square Pharma has current market cap of BDT 177B (or $1.5B), and EV of BDT 122B (or $1.0B).

Market Cap Evolution

Square Pharma Stock Data

As of December 17, 2025, Square Pharma's stock price is BDT 200 (or $2).

See Square Pharma trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$1.0B	$1.5B	XXX	XXX	XXX	XXX	n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Square Pharma Valuation Multiples

Square Pharma's trades at 1.7x EV/Revenue multiple, and 4.6x EV/EBITDA.

See valuation multiples for Square Pharma and 15K+ public comps

Square Pharma Financial Valuation Multiples

As of December 17, 2025, Square Pharma has market cap of $1.5B and EV of $1.0B.

Equity research analysts estimate Square Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Square Pharma's P/E ratio is not available.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$1.5B	XXX	$1.5B	XXX	XXX	XXX
EV (current)	$1.0B	XXX	$1.0B	XXX	XXX	XXX
EV/Revenue	n/a	XXX	1.7x	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	4.6x	XXX	XXX	XXX
EV/EBIT	n/a	XXX	6.5x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	n/a	XXX	7.9x	XXX	XXX	XXX
EV/FCF	n/a	XXX	9.6x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Square Pharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Square Pharma Margins & Growth Rates

Square Pharma's revenue per employee in the last FY averaged $40K, while opex per employee averaged $9K for the same period.

Square Pharma's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Square Pharma's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Square Pharma and other 15K+ public comps

Square Pharma Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	36%	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	n/a	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$40K	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$9K	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	7%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	0%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	22%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial